Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.

Muireann Walton Vadim Pletzer Thomas Teunissen Thomas Lumley Timothy Hanlon

Published in: Drug safety (2023)

A statistically significant association between BNT162b2 vaccination and myo/pericarditis was observed. This association has been confirmed internationally. BNT162b2 was not found to be associated with the other AESIs investigated, except for SOCV following the first dose of BNT162b2 in the 20-39 years age group only, providing reassurances around the safety of the vaccine.

Keyphrases

coronavirus disease
sars cov
high speed